Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21420071 | 0.83 | TRPM2 (0.37) | TSHRGAAALDH1A1HTTTDP1 | |
| SCHEMBL21420062 | 0.83 | TRPM2 (0.37) | TSHRGAAALDH1A1HTTTDP1 | |
| SCHEMBL14555879 | 0.73 | LMNA (0.47) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL14487337 | 0.73 | LMNA (0.47) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL14487939 | 0.73 | LMNA (0.47) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL17066995 | 0.72 | TDP1 (0.32) | TDP1 | |
| SCHEMBL14487851 | 0.72 | LMNA (0.52) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL20078963 | 0.70 | LMNA (0.44) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL14484690 | 0.70 | LMNA (0.53) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL14487345 | 0.70 | LMNA (0.44) | LMNATSHRNPSR1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654827-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2020-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654827-B2 | Therapeutic compounds | HAVCR2, MAVS, EIF2AK2 | LMNA 4352/4885TSHR 4787/4885NPSR1 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.